abstract |
Therapeutically effective amounts of a 3,4-diarylchroman can be administered transdermally by incorporation of the 3,4-diarylchroman in a matrix or liquid reservoir patch suitable for transdermal delivery, which matrix or liquid reservoir patch optionally contains hydrophobic and/or hydrophilic vehicle(s). |